XNCR (Xencor) Valuation Rank


XNCR Xencor Inc XNCR
52 GF Score
Price $15.00
GF Value $9.54
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Xencor Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Xencor Valuation Rank Related Terms

XNCR
52GF Score
Xencor Inc XNCR
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $15.00 is trading 57.2% above its estimated GF Value™ of $9.54. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • Valuation Rank:
  • GF Value™: $9.54 vs. price of $15.00 (57.2% above fair value)
  • GF Score™: 52/100 with 7 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
52GF Score

Get the complete analysis for XNCR

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.00
Price
$9.54
GF Value